A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU])

NCT03139513 · clinicaltrials.gov ↗

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Cobimetinib
DRUG: Vemurafenib

Sponsor

Hoffmann-La Roche